Emergent Biosolutions is pumping $50 million into upgrades at one of its Baltimore plants.
The biopharmaceutical firm said this month that it plans to complete the expansion of the fill/finish facility in Carroll-Camden over three years.
Gaithersburg–based Emergent Biosolutions makes vaccines and therapeutics, including an anthrax vaccine that is manufactured in Baltimore. The Carroll-Camden facility is one of multiple sites in the city, along with a manufacturing operation in Bayview that itself recently doubled in size.
READ FULL ARTICLE HERE